Ernexa Secures $10.5M Financing, Targets Q4 Clinical Trial Start for Lead Cancer Drug
Summary
Ernexa Therapeutics announced significant progress for its lead product candidate, ERNA-101, targeting platinum-resistant ovarian cancer, with an Investigational New Drug (IND) application expected in Q3 2026 and a first-in-human Phase 1 clinical study planned for Q4 2026. Preclinical data demonstrated deep and durable tumor regressions, supporting the program's advancement. Critically, the company highlighted a recent $10.5 million financing, which provides essential capital for these upcoming milestones. This update comes shortly after Ernexa received a Nasdaq delisting notice on March 20th and its last 10-K raised going concern doubts, making the financing and clinical progress highly material. For a micro-cap biotech facing delisting, securing funding and advancing a lead candidate into clinical trials are crucial value inflection points that could significantly impact its future. Investors will closely monitor the IND submission, the initiation of the Phase 1 trial, and any developments regarding the Nasdaq delisting process.
At the time of this announcement, ERNA was trading at $0.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.5M. The 52-week trading range was $0.18 to $4.02. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.